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Abstract. The aim of the present study was to assess the sensi-
tivity, specificity and practicality of using a one‑step nucleic 
acid amplification (OSNA) assay during breast cancer staging 
surgery to predict and discriminate between at least 2 involved 
nodes and more than 2 involved nodes and facilitate the deci-
sion to provide axillary conservation in the presence of a low 
total axillary node tumour burden. A total of 700 consecu-
tive patients, not treated with neo-adjuvant chemotherapy, 
received intraoperative sentinel lymph node (SLN) analysis 
using OSNA for cT1‑T3 cN0 invasive breast cancer. Patients 
with at least one macrometastasis on whole‑node SLN analysis 
underwent axillary lymph node dissection (ALND). The total 
tumour load (TTL) of the macrometastatic SLN sample was 
compared with the non‑sentinel lymph node (NSLN) status of 
the ALND specimen using routine histological assessment. In 
total, 122/683 patients (17.9%) were found to have an OSNA 
TTL indicative of macrometastasis. In addition, 45/122 (37%) 
patients had NSLN metastases on ALND with a total posi-
tive lymph node burden exceeding the American College 
of Surgeons Oncology Group Z0011 trial threshold of two 
macrometastatic nodes. The TTL negative predictive value 
was 0.975 [95% confidence interval (CI), 0.962‑0.988]. The 
area under the curve for the receiver operating characteristic 
curve was 0.86 (95% CI, 0.81‑0.91), indicating that SLN TTL 
was associated with the prediction (and partitioning) of total 
axillary disease burden. OSNA identifies a TTL threshold 
value where, in the presence of involved SLNs, ALND may 
be avoided. This technique offers objective confidence in 
adopting conservative management of the axilla in patients 
with SLN macrometastases.
Introduction
Sentinel lymph node biopsy (SLNB) has replaced complete 
axillary lymph node dissection (ALND) as the current 
standard of care for axillary node staging in patients with 
clinically node‑negative breast cancer (1). When the sentinel 
nodes are found to be free from metastatic disease, no further 
axillary treatment is recommended (1). The role of ALND, 
for patients with positive sentinel lymph nodes, is currently 
being redefined. Research has indicated that patients with 
sentinel lymph node (SLN) micrometastases treated with 
SLNB alone have similar disease‑free and overall survival 
to those receiving ALND (2). This has also been observed 
for stage T1‑2 disease with ≤2 macro‑metastatic SLNs treated 
with breast conservation surgery, whole‑breast radiotherapy 
and adjuvant systemic therapy (3). Therefore, ALND may be 
over‑treatment for patients with early breast cancer and a low 
burden of axillary node involvement.
A reliable intraoperative technique that predicts 
non‑sentinel lymph node (NSLN) involvement would offer 
selective and more conservative treatment of the axilla in a 
single surgical procedure. This would avoid unnecessary 
surgery and its associated morbidity while providing benefits 
to the patient, conserving resources and complying with 
emerging clinical practice guidelines (4).
SLN assessment with one‑step nucleic acid amplification 
(OSNA) provides an intraoperative molecular‑based objective 
whole‑node assessment of SLN disease burden that is indepen-
dent of the size or number of lymph nodes tested (5). For these 
reasons, OSNA has greater potential to predict NSLN involve-
ment than routine histopathology assessment, which cannot 
offer timely intraoperative SLN evaluation, remains subjective, 
categorical, and is exposed to sampling errors with sub‑total 
node assessment (6,7). OSNA amplifies cytokeratin‑19 (CK19) 
mRNA in SLN samples, typically providing a quantitative 
measurement of metastatic disease burden in 35 min. The total 
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CK19 mRNA copy number of a SLN biopsy (total tumour 
load, TTL) may predict NSLN involvement and axillary node 
disease burden, facilitating the decision to proceed with, or 
avoid, complete ALND.
The present study compared SLN OSNA TTL with NSLN 
involvement following ALND, and assessed the sensitivity and 
specificity of TTL, and patient and tumour characteristics to 
predict NSLN metastatic burden. The present findings have 
generated a selective treatment protocol for the conservative 
management of the axilla in patients with early breast cancer 
that may be used in the pre‑ and intraoperative setting.
Patients and methods
Patients. The present study was a retrospective, single‑centre 
cohort study of patients diagnosed with breast cancer from 
symptomatic and screening services. A total of 700 consecutive 
patients (681 females and 3 males; mean age, 62 years; range, 
23‑93 years) treated between December 2012 and August 
2015 at the Royal Hallamshire Hospital (Sheffield, UK) who 
underwent a successful SLN biopsy with OSNA assessment 
were studied. The patients had primary invasive cT1‑3 breast 
carcinoma, a clinically negative axilla, normal pre‑operative 
axillary ultrasound, or benign ultrasound‑guided axillary node 
biopsy, and were medically fit for general anaesthetic and axil-
lary treatment. Patients with prior neo‑adjuvant chemotherapy, 
ipsilateral axillary surgery, recurrent disease or extensive ductal 
carcinoma in situ (DCIS) without invasion were excluded. 
Subset analysis was performed for patients who had metastatic 
axillary disease identified by OSNA and subsequent ALND. 
The following parameters were recorded: Age, tumour size 
and grade, multifocality, histological subtype, type of surgery, 
oestrogen receptor status, human epidermal growth factor 
receptor 2 (HER2) status, Ki67, the presence of lympho vascular 
invasion, total number of SLNs and NSLNs, the number 
of positive and negative SLNs and NSLNs, and ratio of the 
number of positive SLNs to the total number of removed SLNs 
and NSLNs following ALND. CK19 mRNA copy number 
(copies/µl) in each SLN were recorded. CK19 expression was 
not routinely tested on pre‑operative biopsy specimens. For 
statistical analysis, when ≥2 SLNs were involved, the combined 
value of CK19 mRNA copies was calculated. The TTL was 
defined as the total CK19 mRNA copy number in the positive 
SLNs (with units of copies/µl). The TTL of the macrometastatic 
SLN sample was compared with the total lymph node status 
and NSLN status of ALND, following routine histological 
assessment with haematoxylin and eosin staining (8).
SLN identification. SLNs were identified using a standard 
protocol of combination radiopharmaceutical and blue dye, 
as described by Mansel et al (9). 99mTc‑labelled albumin 
nano colloid (Nanocoll®; GE Healthcare Life Sciences, Little 
Chalfont, UK) was injected intradermally (0.1‑0.5 ml) at a single 
periareolar site corresponding to the tumour quadrant; 40 MBq 
the day before surgery or 20 MBq on the day of surgery. Patent 
Blue V dye (Laboratoire Guebet, Aulnay‑sous‑Bois, France), 
2 ml undiluted, was injected subdermally at a single periareolar 
site corresponding to the tumour quadrant immediately prior 
to surgery. Under general anaesthetic, SLNs were identified 
and removed prior to breast tumour excision, and sent on ice to 
the Pathology Department. No more than two nodes were sent 
for assessment by OSNA. Any additional SLNs were sent for 
routine fixation, hematoxylin and eosin staining (8) and delayed 
reporting. Therapeutic local excision, therapeutic mammoplasty 
or mastectomy was performed as part of the planned breast 
cancer treatment. Each SLN, trimmed of fat, was weighed and 
recorded. SLNs weighing <50 mg were too small to be processed 
by OSNA, and were therefore diverted to routine histological 
assessment. SLNs weighing >600 mg were divided into two or 
more pieces and processed separately, and the results combined.
OSNA. The OSNA assay (Sysmex Europe GmbH, Norderstedt, 
Germany) was performed according to the manufacturer's 
protocols, as described by Tsujimoto et al (5). Each SLN 
was homogenized in 4 ml homogenizing buffer on ice. The 
lysate was centrifuged to remove fat, cellular debris and other 
contaminants and the mRNA containing supernatant was 
extracted and diluted. A 2‑µl aliquot of the buffered lymph 
node lysate was used for automated real‑time amplification 
of CK19 mRNA via reverse transcription loop‑mediated 
isothermal amplification with a ready‑to‑use reagent kit on 
the RD‑100i (Sysmex Europe GmbH). The rate of amplifi-
cation was measured spectrophotometrically and the CK19 
copy number was calculated by comparison to a standard 
curve. Based on the number of CK19 mRNA copies/µl, the 
result was assessed in accordance with the cut‑off levels 
determined in a study by Tsujimoto et al (5), with macro-
metastasis (OSNA ++) defined as >5,000 copies/µl of CK19 
mRNA, micrometastasis (OSNA +) as 250‑5,000 copies/µl 
and non‑metastasis (OSNA ‑) as <250 copies/µl. The OSNA 
results were immediately communicated by telephone to the 
surgeon within 45 min of sample receipt. Patients with at 
least one macrometastasis on intraoperative OSNA analysis 
underwent levels I, II and III ALND. Between December 
2012 and June 2013, a positive OSNA result for one or two 
nodes with micro‑metastases also triggered an immediate 
ALND. In June 2013, the departmental protocol was amended 
to recommend the removal of two further nodes for routine 
histological processing, with a delayed ALND if these 
returned macrometastatic involvement.
The remaining lymph nodes not involved in the OSNA test 
were processed according to the UK Breast Cancer pathology 
protocol (8). Lymph nodes <5 mm were bisected whereas larger 
nodes were sliced at 3‑mm intervals and single sections assessed 
using haematoxylin and eosin staining. Immunohistochemical 
staining was not used for evaluation of NSLNs.
Preoperative assessment of axilla. Patients underwent axil-
lary ultrasonography (US) at the time of breast assessment, 
or soon after the diagnosis of breast carcinoma. Those with 
abnormal lymph node morphology according to local protocol 
(cortical thickening 2‑3 mm, focal bulge, rounded shape, 
partial or complete loss of fatty hilum, non‑hilar blood flow, 
or partial/complete replacement of node with mass) underwent 
US‑guided lymph node biopsy. Patients with confirmed inva-
sive disease on lymph node biopsy proceeded to neo‑adjuvant 
therapy or ALND without SLNB.
Patient data were anonymised, and collected retrospec-
tively, without influence on patient therapy. The ethical 
considerations of the present study were approved by the 
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Clinical Effectiveness Unit of the Sheffield Teaching Hospitals 
NHS Trust (Sheffield, UK).
Statistical analysis. Distributions of continuous variables were 
determined by visual inspection of frequency‑distribution 
plots; variables were summarised as the mean and confidence 
interval (after transformation if required), or median and inter-
quartile range, as appropriate. Tests for association between 
categorical variables were determined using the Chi‑square 
and Fisher's exact tests. P<0.05 was considered to indicate a 
statistically significant difference. Receiver operating charac-
teristic (ROC) analyses were performed to compute the area 
under the curve (AUC) to estimate concordance. The statistical 
analysis was conducted using SAS software, version 9.4 (SAS 
Institute, Inc., Cary, NC, USA) for Windows 7.
Results
Clinical cohort. A total of 1,315 patients were diagnosed with 
breast carcinoma between December 2012 and August 2015 
at the institution (Fig. 1). Of these, 700 consecutive patients 
received OSNA during surgery for a preoperatively identified 
cT1‑T3 cN0 breast carcinoma. Sixteen cases were excluded 
from the present study; 15 patients had extensive DCIS only 
and 1 patient had received incomplete neo‑adjuvant therapy. 
There were 681 female patients and 3 male cases (mean age, 
62 years; range, 23‑93 years) in the remaining study cohort. Of 
the cases, 9 were bilateral.
In contrast to the American College of Surgeons Oncology 
Group (ACOSOG) Z0011 study (3), all the patients in our unit 
underwent axillary US prior to breast surgery. Those with 
abnormal lymph node morphology underwent immediate 
US‑guided biopsy, and those with confirmed metastatic disease 
were recommended to undergo ALND without SLNB/OSNA, 
which was the protocol at the time of the present study. These 
assessments removed 14.5% (191/1315) of our total new 
diagnosis patient cohort from analysis. These patients did not 
receive further assessment to explore the role of conservative 
management of the axilla as part of their treatment.
Clinicopathological characteristics. The mean number of 
nodes harvested for OSNA per patient was 1.94, with a total of 
1,356 SLNs assessed. A total of 123/684 patients (17.9%) were 
found to have OSNA CK19 mRNA copy numbers indicative 
of macro‑metastasis and all but 1 patient underwent ALND. In 
total, 45/122 (37%) patients had NSLN metastases on ALND 
with a total positive lymph node burden exceeding the ACOSOG 
Z0011 threshold of two macro‑metastatic nodes (Fig. 2).
The distribution of tumour sizes within the cohort 
displayed the expected log‑normal distribution for total and 
sub‑group distribution of size by node involvement. There 
were 143 tumours with a diameter ≤10 mm, and none were 
associated with >2 macrometastases in ALND. TTL was the 
only clinicopathological variable significantly associated with 
risk of NSLN involvement and three or more positive nodes 
(P<0.0001). Tumour size (P=0.14), tumour grade (P=0.84), 
oestrogen receptor status (P=0.09), HER2 (P=1.00) and 
lymphovascular invasion (P=0.30) were not significantly asso-
ciated with the risk of NSLN involvement and three or more 
positive nodes (data not shown).
TTL, axillary lymph node burden and prediction. Sensitivity 
and specificity of OSNA TTL vs. NSLN status using the 
protocol thresholds of TTL ≥250, ≥5000 and ≥15,000 copies/µl 
are detailed in Table I. Diagnostic accuracy of TTL, as demon-
strated by ROC AUC, was 0.86 (Fig. 3).
In the present cohort, 11.4% (13/114) of the grade 1 
tumours had evidence of SLN or NSLN metastases, compared 
with 19.9% (70/351) of the grade 2 and 19.4% (42/216) of the 
grade 3 tumours. The maximum total axillary burden for any 
grade 1 tumour was four nodes for an 18‑mm tumour.
SLNB TTL vs. total lymph node involvement for the 
entire cohort, and for the subset of patients undergoing 
breast conserving surgery (BCS), was plotted (Figs. 4 and 5, 
respectively). The distribution of NSLN metastases was 
partitioned vertically by the point separation of data found 
at 15,000 copies/µl and horizontally by the two lymph node 
involvement threshold by which the ACOSOG Z0011 trial 
would not recommend ALND (3). BCS was performed in 
499/700 (71.2%) patients and they represented a surrogate 
sub‑group for comparison with the ACOSOG Z0011 (3) trial. 
However, the present group had broader inclusion criteria and 
was selection‑modified by preoperative axillary US filtering. 
In total, 66/499 patients (13.2%) had ALND, 27 (41%) with 
NSLN involvement and 39 (59%) without NSLN involvement. 
In total, 20/23 (87%) patients with TTL >15,000 copies/µl of 
CK19 mRNA had more than two involved NSLNs on ALND. 
Sensitivity, specificity, positive predictive value and negative 
predictive value of SLNB TTL vs. NSLN status using the 
threshold of TTL ≥15,000 copies/µl for the subset of patients 
undergoing BCS are detailed in Table I. For patients with a 
SLNB TTL <15,000 copies/µl and who had ≤2 nodes involved, 
the NPV was 0.983. According to Z0011 criteria, 35/499 (7.0%) 
patients could be regarded as being over‑treated with a 3/499 
(0.6%) false‑negative rate (potential under‑treatment).
Discussion
SLNB remains the standard of care for staging breast carci-
noma in the clinically uninvolved axilla (1). Research has 
suggested that ALND may be safely omitted in patients with 
a low burden of axillary disease (3,10,11), particularly with 
micrometastatic disease only (12), but also where only one or 
two nodes with macrometastases are identified (3). Identifying 
patients who should proceed with ALND has been attempted 
with nomograms (13) and prediction models (7) with varying 
degrees of accuracy. Several studies have reported methods 
to predict ≥4 lymph node metastases (14‑17). However, the 
majority of these prediction models were constructed using 
predictors derived from breast resection specimen pathology, 
such as lymphovascular invasion, and have not been widely 
adopted as they fail to confidently facilitate one‑stage intra-
operative decision making about the role of ALND. A small 
number of studies have reported on the prediction of NSLN 
metastases in SLN‑positive patients, including the use of SLN 
OSNA TTL (7,18,19).
OSNA was formally approved by the UK National Institute 
of Clinical Excellence and included in routine surgical practice 
in 2013 (20). OSNA is at least equally cost effective as routine 
histology; however, it has substantial patient benefits (21,22). It 
remains the only intraoperative diagnostic test recommended 
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for whole‑node analysis for detecting SLN metastases during 
breast surgery in individuals with early invasive breast cancer.
As a categorical diagnostic tool, OSNA alone is insuffi-
cient to determine which patients with macro‑metastatic nodal 
disease may be spared ALND. The present study revealed that 
60.7% of the cohort with macrometastatic lymph nodes on SLN 
OSNA had no further nodal involvement on ALND. Indeed, 
only 7.9% (54/683) of the entire cohort had more than two 
nodes with macrometastases. However, the continuous expo-
nential quantification of TTL extends its utility considerably 
as a predictive tool (7,23‑25). Stratification of CK19 mRNA 
copy numbers facilitates intraoperative decision‑making for 
management of the axilla. In the present cohort of patients, 
the ROC AUC of 0.86 for two node TTL indicated that SLN 
TTL represents a good association with the presence of NSLN 
metastases. However, developing a model that predicts more 
than two node involvement and NSLN involvement is chal-
lenged by the small numbers of patients who satisfy this subset. 
In total, 21% of patients in the ALND arm of the Z0011 trial 
had additional positive nodes (3) whereas this occurred in 37% 
of the present cohort, despite our routine use of preoperative 
axillary US assessment. This observation may reflect a cohort 
of patients with more favourable disease in the ACOSOG 
Z0011 study, and/or higher sensitivity of lower disease burden 
detected with OSNA. Furthermore, the present cohort included 
21/683 (3%) patients with pT3 tumours and the overall mean 
tumour size was 20 mm compared to 16 mm in Z0011 (3). 
The larger proportion of patients with additional NSLN node 
involvement in the present cohort may have contributed to the 
generation of an ROC AUC >0.8. Identifying any predictive 
markers with statistical significance was not possible using 
traditional clinicopathological factors in the present study. 
When lymphovascular invasion was reported in the resection 
specimen, it was twice as likely that NSLN metastases would 
be present than otherwise. If lymphovascular invasion was 
reported as being absent, the likelihood of NSLN metastases 
was 30% less. These findings, however, did not translate into 
statistical significance for predicting the risk of additional 
NSLN disease.
A study by Kubota et al (18) reported a single‑centre stan-
dardised method for SLN detection that used indocyanine green; 
whereas, the types of injection and the use of radioisotope, with 
or without dye, varied according to institutional practice in a 
multi‑centre study by Piñero‑Madrona et al (19). The present 
single‑centre dual technique of SLN detection is uniform and 
standardised (9). Differences in the methods of SLN detection, 
in particular OSNA TTL quantification restricted to two nodes 
in the present study, may account for some of the differences 
observed in ROC AUC values and in the association of NSLN 
positivity with other putative predictive variables. The mean 
number of SLNs removed in the studies by Kubota et al (18) 
and Piñero‑Madrona et al (19) are not reported for comparison. 
An average SLN harvest >2.0 may suggest some persistence in 
retrieval, diluting the residual pool of NSLN with the removal 
of some nodes that would otherwise be accounted for in a 
subsequent ALND analysis. This would impact on how the 
relationship between SLN TTL burden and associated NSLN 
positivity is interpreted and compared in practice.
The present study identified an extension of the TTL 
threshold for conservative management of the axilla beyond 
5,000 to 15,000 copies/µl and confirmed the findings of 
Figure 2. Distribution of the total number of positive nodes in an ALND for 
122 patients with macrometastases. ALND, axillary lymph node dissection.
Figure 1. Cohort distribution flow chart. SLNB, sentinel lymph node biopsy; OSNA, one‑step nucleic acid amplification; ALND, axillary lymph node dissec-
tion; NSLN, non‑sentinel lymph node.
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Peg et al (7). In the present study, 70.0% (14/20) of patients with 
a SLN TTL between 5,000 and 15,000 copies/µl had no further 
metastatic disease identified on ALND. Those patients with 
a SLN TTL ≥15,000 copies/µl continue to attract the recom-
mendation to proceed with ALND. In the present cohort, 43.1% 
(44/102) of these patients (44/683, 6.4% of total cohort) had more 
than two involved nodes in total. The remaining 56.9% (58/683, 
8.5% of total cohort) had only one or two positive nodes, and 
could be regarded as having their axilla over‑treated. In those 
patients who underwent BCS, 20/23 (87%) patients who had 
more than two involved NSLNs on ALND had a SLNB TTL 
>15,000 copies/µl. The 3/23 (13%) patients who had more than 
two nodes involved on ALND following TTL <15,000 copies/µl 
on OSNA was markedly less than the 23% of patients estimated 
to have had residual axillary disease in the non‑ALND arm 
of Z0011, which reported a 0.9 and 1.5% regional recurrence 
rate at 5 and 10 years, respectively, for SLN positive disease 
without ALND (3,26). Our new recommended threshold for 
no ALND of TTL <15,000 copies/µl of CK19 mRNA is also 
markedly less than the recently adjusted threshold demonstrated 
by Peg et al (27) that correlates with disease‑free, local recur-
rence‑free and overall survival. They defined a TTL threshold 
of 25,000 CK19 mRNA copies/µl for a low‑risk group below, 
and a high‑risk group above, this threshold (27).
Table I. Sensitivities and specificities of OSNA TTL of cytokeratin‑19 mRNA copy numbers.
A, OSNA by NSLN using TTL cut‑off of 250a copies/µl for all the patients
 NSLN
 ------------------------------------
OSNA + ‑ Total Sensitivityb Specificityb PPVb NPVb
+ 58 231 289 0.906 (0.835‑0.978) 0.627 (0.589‑0.665) 0.201 (0.155‑0.247) 0.985 (0.973‑0.997)
‑ 6 388 394
Total 64 619 683
B, OSNA by NSLN using TTL cut‑off of 5,000c copies/µl for all patients
 NSLN
 ------------------------------------
OSNA + ‑ Total Sensitivityb Specificityb PPVb NPVb
+ 50 72 122 0.781 (0.680‑0.883) 0.884 (0.858‑0.909) 0.410 (0.323‑0.497) 0.975 (0.962‑0.988)
- 14 547 561
Total 64 619 683
C, OSNA by NSLN using TTL cut‑off of 15,000c copies/µl for all patients
 NSLN
 ------------------------------------
OSNA + ‑ Total Sensitivityb Specificityb PPVb NPVb
+ 44 58 102 0.815 (0.711‑0.918) 0.908 (0.885‑0.930) 0.431 (0.335‑0.528) 0.983 (0.972‑0.992)
- 10 571 581
Total 54 629 683
D, OSNA by NSLN using TTL cut‑off of 15,000c copies/µl for patients undergoing breast conserving surgery
 NSLN
 ------------------------------------
OSNA + ‑ Total Sensitivityb Specificityb PPVb NPVb
+ 20 35 55 0.870 (0.732‑1.000) 0.927 (0.903‑0.950) 0.364 (0.237‑0.491) 0.993 (0.986‑1.000)
‑ 3 441 444
Total 23 476 499
aIndicates micrometastasis; bdata are presented as value (95% confidence interval); cindicates macrometastasis. For NSLN, + indicates present 
and ‑ indicates absent. For OSNA, + indicates TTL cut‑off reached or exceeded and ‑ indicates below TTL cut‑off. OSNA, one‑step nucleic 
acid amplification; TTL, total tumour load; NSLN, non‑sentinel lymph node; PPV, positive predictive value; NPV, negative predictive value.
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ALND is not recommended for patients when the SLNB is 
deemed negative (OSNA TTL <250 copies/µl) or interpreted 
as micrometastatic disease only (OSNA TTL between 250 and 
5,000 copies/µl) [25.0% (171/683) in the present cohort] (2). 
Only 2.3% (4/171) of these patients had more than two 
involved nodes. We would recommend that patients with a 
tumour of <10 mm diameter receive standard SLNB without 
OSNA. Only 5.6% (8/143) of these patients had evidence of 
metastatic axillary disease, none had more than two involved 
nodes and the rate of involvement was less than the reported 
9% false‑negative rate for a two‑node assessment (28).
False‑negative SLN assessment by OSNA is very low 
(1.4%) and also well within the two SLNB false‑negative rate 
of 9.0% (29). We suggest that pre‑SLNB testing of the tumour 
biopsy specimen with CK19 immunostaining is unnecessary or 
restricted to defining an inclusion role for OSNA in uncommon 
circumstances where absent or minimal CK19 mRNA expres-
sion may be suspected, such as metaplastic or high Ki67 scoring 
tumours, inversely reflecting the aggressive nature of the 
tumour (29,30). Much higher rates of CK19 negative tumours, 
up to 20%, have been reported; however, these are related to 
assessments of CK19 immunostaining of protein rather than 
Figure 6. Protocol for management of the clinically uninvolved axilla using 
OSNA and TTL. OSNA, one‑step nucleic acid amplification; TTL, total 
tumour load (of cytokeratin‑19 mRNA copy numbers); cT1‑T3 and cN0, 
TNM classification; US, ultrasound (of axilla); ALND, axillary lymph node 
dissection; SLNB, sentinel lymph node biopsy.
Figure 5. Sentinel lymph node biopsy TTL vs. total lymph node involvement 
for patients undergoing breast conservation surgery. TTL, total tumour load 
(of CK19 mRNA copy numbers); LN, lymph node; NSLN, non‑sentinel 
lymph node; CK19, cytokeratin‑19.
Figure 4. Sentinel lymph node biopsy TTL vs. total lymph node involve-
ment. TTL, total tumour load (of CK19 mRNA copy numbers); LN, lymph 
node; NSLN, non‑sentinel lymph node; ACOSOG Z0011, American College 
of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized 
trial (3,26); ALND, axillary lymph node dissection; OSNA, one‑step nucleic 
acid cytokeratin‑19 amplification assay; CK19, cytokeratin‑19.
Figure 3. Receiver operating characteristic curve demonstrating diagnostic 
accuracy. Area under the curve, 0.8618 (95% confidence interval, 0.8119‑0.9118).
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CK19 mRNA levels (30‑32). A study by Pegolo et al (33), 
reported no correlation between CK19 protein expression 
and CK19 mRNA levels within primary breast cancer or the 
associated metastatic lymph node. In their study, CK19 mRNA 
was detected in all cases by OSNA. Similarly, a study by 
Fujisue et al (29), reported that the incidence of CK19 nega-
tive tumours was 12.3% with immunostaining; however, CK19 
mRNA expression was absent in only 1.4% of the cases (29). 
These observations have allowed us to generate a protocol for 
the management of the axilla in our practice (Fig. 6).
The ACOSOG Z0011 trial demonstrated non‑inferiority of 
no ALND for patients with T1 or T2 primary breast lesions 
and one or two positive axillary lymph nodes having BCS, 
whole‑breast radiotherapy and adjuvant systemic therapy (3). 
The findings and recommendations of the Z0011 trial have 
attracted notable controversy and review. These issues have 
been extensively discussed (34), recently updated (26) and 
remain defensible in clinical practice. Regardless of contro-
versy, it is clear that not all patients with a positive SLN require 
an ALND if there is minimal risk of axillary recurrence or 
compromise of their overall survival. In the present study, 
92.1% of patients had two or less positive nodes on ALND. 
Axillary recurrence risk is low, even with a reported false-
negative SLNB rate varying between 6.7 and 14.8% (1,9,35,36). 
The reported rates of isolated axillary recurrence in SLN 
negative disease are ~0.6% at 3 years and 1.1% at 5 years (37), 
similar to 0.9 and 1.5% reported at 5 and 10 years, respec-
tively, for SLN-positive disease without ALND in the Z0011 
trial (3,26). It appears illogical to remain preoccupied with 
the requirement to perform ALND on patients with cT1‑T2 
disease and a clinically negative axilla when local recurrence 
is 2.5‑11 fold more likely to occur in the fully irradiated breast 
than the partially irradiated ipsilateral axilla (26). These rates 
of axillary recurrence are markedly less than the rates of 
ALND morbidity affecting up to 36% of patients with lymph-
oedema (13‑19.1%), paraesthesia (31‑37.7%), pain (21.1%) and 
decreased mobility (11.3%) (38,39).
In the present study, the results of testing two nodes have 
provided a robust threshold for clinical decision‑making. 
Four‑node testing would potentially alter the management of 
just 8.5% (58/683) of the present cohort. Used in combination 
with TTL, categorical four‑node status may facilitate the 
intraoperative decision to perform ALND along traditional 
lines, bridging and translating the utility of SLNB TTL in 
existing models of prognosis and in guiding adjuvant treat-
ment. Enhancement in prediction and treatment guidance is 
expected with extended genomic biomarker analyses of the 
OSNA sample homogenate (40).
The observation that 92.1% of the present total cohort had 
two or less nodes involved with macrometastatic disease and 
63% of the present patients with positive SLNs did not have 
additional node metastases supports the move toward selective 
conservative axillary management. The present study did not 
demonstrate any benefit in performing ALND on patients with 
an OSNA TTL ≥15,000 copies/µl. However, while there are 
no studies that confirm otherwise, it remains practical to iden-
tify the ACOSOG two‑node macrometastases threshold for 
guiding clinical practice, informing systemic treatment and 
axillary radiotherapy field planning, and to putatively improve 
local disease control in the axilla.
The present study confirmed the thresholds and utility 
of including OSNA TTL in intraoperative ALND decision 
modelling that predict and discriminate between ≤2 involved 
nodes and >2 involved nodes. The present study identified, 
and confirmed, an extended threshold of OSNA TTL that 
may independently predict when ALND may be avoided, 
facilitating adoption of the emerging acceptance and recom-
mendations for selective conservative management of the node 
positive axilla.
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